A Phase IIb Study of ABT‐494, a Selective JAK‐1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti–Tumor Necrosis Factor Therapy

To compare the efficacy and safety of ABT‐494, a novel selective JAK‐1 inhibitor, with placebo in patients with moderate‐to‐severe rheumatoid arthritis (RA) and an inadequate response or intolerance to at least 1 anti–tumor necrosis factor (anti‐TNF) agent.

• Publication year

  2016

• Venue

  Arthritis & Rheumatology

• Publication date

  2016-07-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/art.39801PMID 27389975PMCID 5132116
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis

  2016cited by this paper
• VX‐509 (Decernotinib), an Oral Selective JAK‐3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis

  2016cited by this paper
• Efficacy and Safety of ABT‐494, a Selective JAK‐1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

  2016cited by this paper
• Emerging Therapies for Rheumatoid Arthritis

  2016cited by this paper
• THU0178 Relationship Between NK Cell Count and Important Safety Events in Rheumatoid Arthritis Patients Treated with Tofacitinib

  2015cited by this paper
• Adjuvant Therapy Reduces Rate of Dissemination but Shortens Survival Thereafter.

  2015cited by this paper
• LB0001 Baricitinib, an Oral Janus Kinase (JAK)1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and An Inadequate Response to CDMARD Therapy: Results of the Phase 3 RA-Build Study

  2015cited by this paper
• OP0029 Baricitinib, An Oral Janus Kinase (JAK)1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to TNF Inhibitors: Results of the Phase 3 RA-Beacon Study

  2015cited by this paper
• Selective JAK inhibitors in development for rheumatoid arthritis

  2014influential reference
• Tofacitinib versus methotrexate in rheumatoid arthritis.

  2014cited by this paper
• Tofacitinib versus methotrexate in rheumatoid arthritis.

  2014cited by this paper
• SP0001 The Value of Health Professionnals in Europe: A Personal View and Vision for the Future

  2014cited by this paper
• Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate

  2014cited by this paper
• THU0127 Pharmacodynamics of A Novel JAK1 Selective Inhibitor in Rat Arthritis and Anemia Models and in Healthy Human Subjects

  2014cited by this paper
• Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.

  2013cited by this paper
• Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis

  2013cited by this paper
• Janus kinase inhibitors in autoimmune diseases

  2013cited by this paper
• Emerging therapies for rheumatoid arthritis

  2013cited by this paper
• Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis.

  2012cited by this paper
• Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice

  2012cited by this paper
• Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.

  2012cited by this paper
• 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

  2010cited by this paper
• UvA-DARE (Digital Academic Repository) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative Aletaha,

  2010cited by this paper
• Rheumatoid arthritis classifi cation criteria : an American College of Rheumatology / European League Against Rheumatism collaborative initiative

  2010cited by this paper
• Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

  2008cited by this paper
• The JAK-STAT Signaling Pathway: Input and Output Integration1

  2007cited by this paper
• Standardizing assessment and reporting of adverse effects in rheumatology clinical trials II: the Rheumatology Common Toxicity Criteria v.2.0.

  2007influential reference
• Sustained benefit in rheumatoid arthritis following one course of rituximab: improvements in physical function over 2 years.

  2006cited by this paper
• Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis

  2005cited by this paper
• Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score

  2005cited by this paper
• Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.

  2004cited by this paper
• A simplified disease activity index for rheumatoid arthritis for use in clinical practice.

  2003cited by this paper
• A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.

  2000cited by this paper
• American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis.

  1995cited by this paper
• Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

  1995cited by this paper
• The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials.

  1993cited by this paper
• The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials

  1993cited by this paper
• Revised criteria for the classification of rheumatoid arthritis.

  1990cited by this paper
• The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

  1988cited by this paper
• Measurement of patient outcome in arthritis.

  1980cited by this paper

• The efficacy and safety of biologic or targeted synthetic DMARDs in rheumatoid arthritis treatment: one year of review 2024.

  2025cites this paper
• Real-world effectiveness and retention rate of upadacitinib in patients with rheumatoid arthritis: results from a multicentre study

  2025cites this paper
• 2024 Update of the Japan College of Rheumatology Clinical Practice Guidelines for the Management of Rheumatoid Arthritis - secondary publication.

  2025cites this paper
• The efficacy and safety of Janus kinase inhibitors in adults with rheumatoid arthritis: a systematic review and cumulative meta-analysis.

  2025cites this paper
• Damage-associated molecular patterns (DAMPs) in diseases: implications for therapy

  2025cites this paper
• Structure-Based Design of Small-Molecule Inhibitors of Human Interleukin-6

  2025cites this paper
• Fatal Suicide Attempt with Upadacitinib (Rinvoq®) in an Adolescent: A Case Report

  2025cites this paper
• Cumulative incidence and risk of infection in patients with rheumatoid arthritis treated with janus kinase inhibitors: A systematic review and meta-analysis

  2024cites this paper
• Network‐Based Drug Repurposing and Genomic Analysis to Unveil Potential Therapeutics for Monkeypox Virus

  2024cites this paper
• Systematic review and meta-analysis for the 2024 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis.

  2024cites this paper
• Relationship between lymphocyte count and risk of infection in Japanese rheumatoid arthritis patients treated with tofacitinib.

  2024cites this paper
• Safety of Janus kinase inhibitors compared to biological DMARDs in patients with rheumatoid arthritis and renal impairment: the ANSWER cohort study

  2024cites this paper
• Efficacy and Safety of Upadacitinib in Rheumatoid Arthritis: Real-Life Experience from a Prospective Longitudinal Multicentric Study

  2024influential citation
• Novel insights into the ROCK-JAK-STAT signaling pathway in upper respiratory tract infections and neurodegenerative diseases

  2024cites this paper
• Comparative Efficacy and Safety of JAK Inhibitors in the Management of Rheumatoid Arthritis: A Network Meta-Analysis

  2024cites this paper
• Utilization of phase I studies for target validation of first-in-class drugs.

  2024cites this paper
• Real-World Experience With Janus Kinase Inhibitors in Immune-Mediated Diseases: Clinical Experience of a University Hospital

  2024cites this paper
• Pyrazine-based small molecule kinase inhibitors: clinical applications and patent review (2019-2023).

  2024cites this paper
• Pathogenesis and treatment of Sjogren’s syndrome: Review and update

  2023cites this paper
• JAK inhibitors and autoimmune rheumatic diseases.

  2023cites this paper
• Upadacitinib for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA)

  2023cites this paper
• Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story

  2023cites this paper
• Successful Remission with Upadacitinib in Two Patients with Anti-TNF-Refractory Macular Edema Associated with Behçet’s Uveitis

  2023cites this paper
• Double-edged sword of JAK/STAT signaling pathway in viral infections: novel insights into virotherapy

  2023cites this paper
• Impact of upadacitinib on the risk of digestive events in patients with rheumatoid arthritis: A systematic review and meta-analysis of randomized controlled trials

  2023cites this paper
• UPADACITINIB IN ACTION: EFFICACY AND SAFETY IN THE TREATMENT OF RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND AXIAL SPONDYLOARTHRITIS

  2023influential citation
• Long-Term Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: Final Results from the BALANCE-EXTEND Open-Label Extension Study

  2023cites this paper
• Nanomedicine is more than a supporting role in rheumatoid arthritis therapy.

  2023cites this paper
• Upadacitinib for Patients with Rheumatoid Arthritis: A Comprehensive Review

  2023cites this paper
• Safety of Oral Janus Kinase Inhibitors in the Treatment of Moderate-to-Severe Atopic Dermatitis

  2023cites this paper
• A Meta-Analysis Evaluating the Effectiveness and Safety of Upadacitinib in Treating Rheumatoid Arthritis in Patients With Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs

  2023influential citation
• Utility of Modeling and Simulation Approach to Support the Clinical Relevance of Dissolution Specifications: a Case Study from Upadacitinib Development

  2022cites this paper
• Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trial.

  2022cites this paper
• The Effect of Upadacitinib on Lipid Profile and Cardiovascular Events: A Meta-Analysis of Randomized Controlled Trials

  2022cites this paper
• Clinical Efficacy and Safety of Psoriasis Treatments in Patients with Concomitant Metabolic Syndrome: A Narrative Review

  2022cites this paper
• Upadacitinib for the Treatment of Rheumatoid Arthritis: An Extensive Review

  2022cites this paper
• Efficacy and Safety of JAK Inhibitors for Rheumatoid Arthritis: A Meta-Analysis

  2022cites this paper
• Cardiovascular and Venous Thromboembolic Risk With Janus Kinase Inhibitors in Immune‐Mediated Inflammatory Diseases: A Systematic Review and Meta‐Analysis of Randomized Trials

  2022cites this paper
• DDDT_A_340459 1897..1913

  2022cites this paper
• Evaluating Upadacitinib in the Treatment of Moderate-to-Severe Active Ulcerative Colitis: Design, Development, and Potential Position in Therapy

  2022cites this paper
• Targeting Janus Kinase (JAK) for Fighting Diseases: The Research of JAK Inhibitor Drugs.

  2022cites this paper
• Evaluation of response to 13-valent conjugated pneumococcal vaccination in patients with rheumatoid arthritis receiving upadacitinib: results from a phase 2 open-label extension study

  2022cites this paper
• Affecting the effectors: JAK inhibitors modulation of immune cell numbers and functions in patients with rheumatoid arthritis

  2022cites this paper
• Janus Kinase Inhibitors Improve Disease Activity and Patient-Reported Outcomes in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of 24,135 Patients

  2022cites this paper
• Evaluating upadacitinib for the treatment of psoriatic arthritis

  2022cites this paper
• JAK Inhibitors and Modulation of B Cell Immune Responses in Rheumatoid Arthritis

  2021cites this paper
• A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): An interim 24-week analysis

  2021cites this paper
• Toward Overcoming Treatment Failure in Rheumatoid Arthritis

  2021cites this paper
• Immunosuppression in Rheumatologic and Auto-immune Disease.

  2021cites this paper
• The involvement of JAK/STAT signaling pathway in the treatment of Parkinson's disease.

  2021cites this paper
• Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry

  2021cites this paper
• Management of Rheumatoid Arthritis: An Overview

  2021cites this paper
• Targeting of Janus Kinases Limits Pro-Inflammatory but Also Immunosuppressive Circuits in the Crosstalk between Synovial Fibroblasts and Lymphocytes

  2021cites this paper
• JAK-Hemmer bei adulter und juveniler Arthritis

  2021cites this paper
• The role of upadacitinib in the treatment of moderate-to-severe active rheumatoid arthritis

  2021cites this paper
• Investigating Synthetic Controls with Randomized Clinical Trial Data in Rheumatoid Arthritis Studies

  2021cites this paper
• Current and future status of JAK inhibitors.

  2021cites this paper
• EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis

  2021cites this paper
• Emerging protein kinase inhibitors for the treatment of rheumatoid arthritis

  2021cites this paper
• Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis

  2021cites this paper
• JAK Family Inhibitors for Autoimmune Diseases

  2021cites this paper
• Upadacitinib Treatment Improves Symptoms of Bowel Urgency and Abdominal Pain, and Correlates With Quality of Life Improvements in Patients With Moderate to Severe Ulcerative Colitis

  2021cites this paper
• Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE)

  2021cites this paper
• The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan

  2021cites this paper
• Early phase studies of JAK1 selective inhibitors in rheumatoid arthritis

  2021cites this paper
• Effect of janus kinase inhibitors and methotrexate combination on malignancy in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials

  2021cites this paper
• Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis

  2021cites this paper
• Interleukin-6: obstacles to targeting a complex cytokine in critical illness

  2021cites this paper
• Regulation of the expression of proinflammatory cytokines induced by SARS-CoV-2

  2021cites this paper
• Small Molecule Inhibitors in the Treatment of Rheumatoid Arthritis and Beyond: Latest Updates and Potential Strategy for Fighting COVID-19

  2020cites this paper
• Inhibition of JAK/STAT signaling in rheumatologic disorders: the expanding spectrum.

  2020cites this paper
• Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results from Two Randomized, Controlled Phase 2b Trials

  2020cites this paper
• Safety of Janus Kinase Inhibitors in Patients with Inflammatory Bowel Diseases or Other Immune-mediated Diseases: a Systematic Review and Meta-Analysis.

  2020cites this paper
• The role of JAK/STAT signaling pathway and its inhibitors in diseases.

  2020cites this paper
• Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.

  2020cites this paper
• Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis.

  2020cites this paper
• Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme

  2020cites this paper
• Inhibiteurs de la signalisation JAK/STAT au cours des maladies rhumatologiques : un spectre grandissant

  2020cites this paper
• Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study

  2020cites this paper
• Inflammatory Arthritis: Rheumatoid Arthritis

  2020cites this paper
• Evaluating upadacitinib for the treatment of rheumatoid arthritis

  2020cites this paper
• A review of upadacitinib in rheumatoid arthritis

  2020cites this paper
• Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19

  2020cites this paper
• JAK-STAT inhibitors: Immersing therapeutic approach for management of rheumatoid arthritis.

  2020cites this paper
• JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future

  2020cites this paper
• An Update for the Clinician on Biologics for the Treatment of Psoriatic Arthritis

  2020cites this paper
• Acute respiratory viral adverse events during use of antirheumatic disease therapies: A scoping review

  2020cites this paper
• State of the art: approved and emerging JAK inhibitors for rheumatoid arthritis

  2020cites this paper
• Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib

  2020cites this paper
• Современные представления о терапии увеитов при иммуновоспалительных ревматических заболеваниях

  2020cites this paper
• Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research

  2020cites this paper
• The JAK1 Selective Inhibitor ABT 317 Blocks Signaling Through Interferon-γ and Common γ Chain Cytokine Receptors to Reverse Autoimmune Diabetes in NOD Mice

  2020cites this paper
• The progress of rheumatology in the 21st century potential uses of upadacitinib in rheumatoid arthritis and other inflammatory rheumatic diseases

  2020cites this paper
• Efficacy and safety of jakinibs in rheumatoid arthritis: a systematic review and meta-analysis

  2020cites this paper
• Efficacy and safety of tofacitinib for immune-mediated inflammatory rheumatic diseases (Part I)

  2020cites this paper
• E cacy and safety of jakinibs in rheumatoid arthritis: A systematic review and meta-analysis

  2020cites this paper
• upadacitinib, tofacitinib, and baricitinib

  2020cites this paper
• Artrite idiopatica giovanile

  2020cites this paper
• Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical Trials

  2019cites this paper
• Development of In Vitro–In Vivo Correlation for Upadacitinib Extended-Release Tablet Formulation

  2019cites this paper